Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 5/20 | 0.39 |
| ▸ | BACE1 | P56817 | 5/20 | 0.39 |
| ▸ | BCHE | P06276 | 5/20 | 0.39 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | DRD4 | P21917 | 3/20 | 0.35 |
| ▸ | DRD3 | P35462 | 3/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4290290 | 0.86 | ACHE (0.45) | LTA4HACHEBACE1BCHESLC6A12 | |
| SCHEMBL4292501 | 0.83 | LTA4H (0.48) | LTA4HACHEBACE1DRD2DRD4 | |
| SCHEMBL4282272 | 0.83 | LTA4H (0.48) | LTA4HACHEBACE1DRD2DRD4 | |
| SCHEMBL4422792 | 0.83 | LTA4H (0.48) | LTA4HACHEBACE1DRD2DRD4 | |
| SCHEMBL4291279 | 0.83 | ACHE (0.46) | LTA4HACHEBACE1BCHESLC6A12 | |
| SCHEMBL4292168 | 0.82 | ACHE (0.45) | LTA4HACHEBACE1BCHEDRD2 | |
| SCHEMBL4294444 | 0.81 | ACHE (0.48) | LTA4HACHEBACE1BCHEDRD2 | |
| SCHEMBL4287399 | 0.81 | LTA4H (0.48) | LTA4HACHEBACE1BCHEDRD4 | |
| SCHEMBL4286385 | 0.80 | TSHR (0.49) | LTA4HACHEBACE1BCHEDRD2 | |
| SCHEMBL4284730 | 0.80 | ACHE (0.46) | LTA4HKDM4EGAAACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | LTA4H 1197/4885KDM4E 760/4885GAA 1381/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | LTA4H 1197/4885KDM4E 760/4885GAA 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.